AIMT Aimmune Therapeutics, Inc.

17.15
-1.11  -6%
Previous Close 18.26
Open 18.20
Price To book 3.47
Market Cap 863.37M
Shares 50,342,000
Volume 289,501
Short Ratio 10.54
Av. Daily Volume 322,817

SEC filingsSee all SEC filings

  1. 8-K - Current report 17874181
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17822411
  3. 8-K - Current report 17822321
  4. CT ORDER - Confidential treatment order 17755886
  5. 8-K - Current report 17761437

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment to be initiation announced May 11, 2017.
AR101 RAMSES
Peanut Allergy
Phase 3 initiated January 2016. Enrollment completion announced November 28, 2016. Top-line data due 4Q 2017.
AR101
Peanut Allergy

Latest News

  1. Why These Drug Stocks May Surge
  2. Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
  3. Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16
  4. Aimmune Therapeutics reports 1Q loss
  5. Aimmune Therapeutics Announces First Quarter 2017 Financial Results
  6. Biotechs Cruise On 6-Day Upswing Despite Price Target Cuts For This Duo
  7. Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer
  8. Should You Get Rid of Aimmune Therapeutics (AIMT) Now?
  9. Edited Transcript of AIMT earnings conference call or presentation 15-Mar-17 12:00pm GMT
  10. Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
  11. Aimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017
  12. Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
  13. Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March
  14. Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
  15. Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback
  16. Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
  17. Hedge Funds Aren’t Crazy About Aimmune Therapeutics Inc (AIMT) Anymore
  18. Aimmune Therapeutics Appoints Scientific Advisory Board of World-Renowned Food Allergy Experts
  19. Aimmune Closes Enrolment in Phase III Peanut Allergy Study